MaaT Pharma SA (EPA:MAAT)
7.30
-0.38 (-4.95%)
At close: Jan 30, 2026
MaaT Pharma Revenue
MaaT Pharma had revenue of 2.43M EUR in the half year ending June 30, 2025, with 76.12% growth. This brings the company's revenue in the last twelve months to 3.92M, up 52.55% year-over-year. In the year 2024, MaaT Pharma had annual revenue of 3.22M with 44.34% growth.
Revenue (ttm)
3.92M
Revenue Growth
+52.55%
P/S Ratio
29.98
Revenue / Employee
60.34K
Employees
65
Market Cap
117.57M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.22M | 988.00K | 44.34% |
| Dec 31, 2023 | 2.23M | 798.00K | 55.80% |
| Dec 31, 2022 | 1.43M | 458.00K | 47.12% |
| Dec 31, 2021 | 972.00K | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cellectis | 70.36M |
| Genfit | 45.13M |
| Adocia | 12.88M |
| Fermentalg | 12.78M |
| Innate Pharma | 12.64M |
| Transgene | 7.58M |
| Sensorion | 5.65M |
| ABIONYX Pharma | 4.33M |